UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized, controlled, open-labeled interventional clinical trial is to
test the efficacy and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in the
treatment of severe and critical COVID-19 patients. The main questions it aims to answer are:
1. The efficacy of UC-MSCs in the treatment of severe and critical COVID-19 patients. 2. The
safety of UC-MSCs in the treatment of severe and critical COVID-19 patients. 3. The potential
immune mechanisms of UC-MSCs in the treatment of severe and critical COVID-19 patients.
Participants will receive standard therapy, Paxlovid treatment or the UC-MSCs treatment. For
the standard treatment, it will be conducted according the 9th edition of Chinese guidelines
for COVID-19 infection. For UC-MSCs treatment, participants will be given UC-MSCs
instillation at the first and fourth day after assignment. Blood examples will be taken at
indicated time for arterial blood gas analysis and other tests. And participants should also
objectively report their symptoms change and other information related to the treatment as
listed the research protocol.